finanzen.net
Commerzbank Zertifikate ist jetzt Societe Generale Zertifikate. Mehr erfahren!-w-
26.03.2020 21:42

Evolve BioSystems, Inc. Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis

Werbung

DAVIS, Calif., March 26, 2020 /PRNewswire/ -- Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis. The study will assess the effects of introducing a specific gut bacterium, Bifidobacterium longum subspecies infantis (activated B. infantis EVC001, marketed as Evivo®) in inhibiting the onset of atopic dermatitis, the most prevalent pediatric skin disorderi, in the first year of life. The agreement was facilitated by Johnson & Johnson Innovation LLC.

"Atopic dermatitis is not just a debilitating condition for millions of children, but is also a gateway condition associated with numerous chronic conditions that carry a lifelong physical, emotional and financial burden," said David Kyle, PhD, Chairman of the Board and Chief Scientific Officer, Evolve BioSystems, Inc. "This study looks to demonstrate whether the introduction of B. infantis EVC001 to the infant gut microbiome will deflect the development of atopic dermatitis and establish a path to lifelong health."

Atopic dermatitis is an immunological disease condition that affects up to 1 in 5 children, with 60% of cases presenting by age one year.ii Atopic dermatitis has been implicated in predisposing children to a range of pediatric health conditions ranging from food allergies to asthma.iii  These individuals also have an increased risk of other conditions associated with inflammation, such as inflammatory bowel disease and rheumatoid arthritis, and are at increased risk of attention deficit/hyperactivity disorder and depressioniv. The annual cost burden of atopic dermatitis in the US exceeds $5 billionv.

Restoring Good Health Through the Gut Microbiome
The gut microbiome is made-up of trillions of microorganisms that live in the gastrointestinal tract of newborns. B. infantis is a critical beneficial bacteria required for proper development of the infant gut microbiome. B. infantis EVC001 transforms Human Milk Oligosaccharides (HMOs) into quickly available energy for the intestinal cells. This lowers the gut pH, reducing potential pathogens by 80%. The loss of B. infantis due to C-section delivery and antibiotic use is linked to higher risk for atopic dermatitis, as well as a six-fold higher incidence of allergies and of type 1 diabetes in children.vi

Study Details
The study, a proof-of-concept, randomized, double-blind, placebo-controlled, two-arm parallel study, will be conducted in collaboration with Janssen. Investigators will enroll infants who are less than 15 days old, with a genetic predisposition to allergic conditions, and who are breastfed, with maternal intent to maintain breastfeeding through three months of age. Study participants will be given either daily single doses of a supplement with B. infantis (EVC001) or a placebo for a 12-week period, and then monitored for signs of atopic dermatitis, skin rash, diaper rash and itch over the next 2 years.

About Evolve BioSystems, Inc.
Evolve BioSystems, Inc. is a privately held microbiome company dedicated to researching solutions to establish, restore, and maintain a healthy gut microbiome. Evolve is a portfolio company of the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation. Evolve is a spin-off from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components.

The legal entity to the agreement with Evolve is Johnson & Johnson Consumer, Inc.

ihttps://www.ajmc.com/journals/supplement/2017/atopic-dermatitis-focusing-on-the-patient-care-strategy-in-the-managed-care-setting/overview-of-atopic-dermatitis-article
iihttps://www.ajmc.com/journals/supplement/2017/atopic-dermatitis-focusing-on-the-patient-care-strategy-in-the-managed-care-setting/overview-of-atopic-dermatitis-article
iii https://acaai.org/allergies/types-allergies/skin-allergy/eczema-atopic-dermatitis
ivhttps://ghr.nlm.nih.gov/condition/atopic-dermatitis
vhttps://www.ncbi.nlm.nih.gov/pubmed/27616422
vi Vatanen T. et al., Cell. 2016

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/evolve-biosystems-inc-announces-collaboration-with-janssen-to-study-the-impact-of-b-infantis-evc001-in-the-reduction-of-atopic-dermatitis-301030643.html

SOURCE Evolve BioSystems

Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

Dow startet fester -- DAX stabilisiert sich -- Rekordeinbruch bei EU-Wirtschaftsstimmung -- RATIONAL kürzt Dividendenvorschlag -- PUMA, ABB, easyJet, ING, Ceconomy, Bayer im Fokus

Medizintechnik-Aktien profitieren - Sonderkonjunktur durch Virus. Bayer stellt eigene Kapazitäten für Covid-19-Tests zur Verfügung. INDUS rechnet mit deutlichem Umsatzrückgang. Ströer: Höhere Abschreibungen und Steuern drücken auf Gewinnwachstum. SAF Holland fährt Werke teilweise herunter.

Die 5 beliebtesten Top-Rankings

Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
DAX: Die größten Verluste an nur einem Tag
An diesem Tagen verbuchte der DAX das höchste Minus
Diese Aktien und Anleihen hat George Soros im Depot (Q4 2019)
Änderungen im Portfolio
Welche Marken sind vorne mit dabei?
BrandZ-Ranking: Das sind die wertvollsten deutschen Marken
Die Länder mit den größten Goldreserven
Wer lagert das meiste Gold?
mehr Top Rankings

Umfrage

Welcher der folgenden Faktoren ist Ihnen bei der Auswahl eines Emittenten am wichtigsten?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Shell (Royal Dutch Shell) (A)A0D94M
Lufthansa AG823212
Daimler AG710000
Wirecard AG747206
Allianz840400
Infineon AG623100
Amazon906866
Microsoft Corp.870747
Deutsche Bank AG514000
BayerBAY001
BASFBASF11
BioNTech SE (spons. ADRs)A2PSR2
Volkswagen (VW) AG Vz.766403
Airbus SE (ex EADS)938914
NEL ASAA0B733